1119643-91-2

Upstream product

• 1117680-74-6 5,6,6a,7,8,9-hexahydro-4H-2-phenalenylamine 
• 51934-41-9 4-iodobenzoic acid ethyl ester 

Downstream Products

• 1627941-48-3 ethyl 4-[N-methyl-(5,6,6a,7,8,9-hexahydro-4H-2-phenalenyl)-amino] benzoate 
• 1119644-02-8 ethyl 4-[N-ethyl-(5,6,6a,7,8,9-hexahydro-4H-2-phenalenyl)amino]benzoate 
• 1119644-07-3 Ethyl 4-[N-cyclopropylmethyl-(5,6,6a,7,8,9-hexahydro-4H-2-phenalenyl)amino]benzoate 
• 1119643-99-0 4-[N-methyl-(5,6,6a,7,8,9-hexahydro-4H-2-phenalenyl)amino]benzoic acid 
• 1119644-09-5 4-[N-cyclopropylmethyl-(5,6,6a,7,8,9-hexahydro-4H-2-phenalenyl)amino]benzoic acid 
• 1119643-93-4 4-[N-(5,6,6a,7,8,9-hexahydro-4H-2-phenalenyl)amino]benzoic acid 

Relevant academic research and scientific papers

Diarylamines incorporating hexahydrophenalene or octahydrobenzoheptalene as Retinoid X Receptor (RXR)-specific agonists

Selective ligands for retinoic acid receptors (RARs) and for retinoid X receptors (RXRs) are required for both biological studies and therapeutic purposes. We have synthesized a series of diarylamines incorporating hexahydrophenalene or octahydrobenzoheptalene as a hydrophobic moiety and examined their activities towards RARs and RXRs. Most of these compounds showed agonistic activity towards RXRs, but were inactive towards RARs. These RXR-specific ligands showed synergistic activity in RARα,β ligand-induced terminal differentiation of leukemia cell line HL-60.

TRICYCLIC AMINE COMPOUND

A compound represented by the following general formula (I): [wherein R1 represents hydrogen atom or a C16 alkyl group, A and B represent -(CH2)2-, -(CH2)3- or -(CH2)4